Trial Profile

LIO-1: A Phase 1b/2, Open-Label Study to Evaluate the Safety and Efficacy of Lucitanib in Combination With Nivolumab in Patients With An Advanced, Metastatic Solid Tumor

Status: Active, no longer recruiting

Phase of Trial: Phase I/II

Latest Information Update: 12 Mar 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Lucitanib (Primary) ; Nivolumab (Primary)
Indications Anal cancer; Cervical cancer; Endometrial cancer; Fallopian tube cancer; Gynaecological cancer; Ovarian cancer; Peritoneal cancer; Solid tumours
Focus Adverse reactions; Therapeutic Use
Acronyms LIO-1
Sponsors Clovis Oncology [CEASED]

Most Recent Events

08 Mar 2024 This trial has been discontinued in Italy, according to European Clinical Trials Database record.
23 Feb 2023 This trial has been discontinued in Austria, according to European Clinical Trials Database record.
11 Feb 2023 This trial has been discontinued in Germany, according to European Clinical Trials Database record.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com